-
- 古川 敦子
- 高松赤十字病院泌尿器科
-
- 沼田 明
- 高松赤十字病院泌尿器科
-
- 今川 章夫
- 高松赤十字病院泌尿器科
-
- 海部 泰夫
- 海部医院
-
- 隅蔵 透
- 香川医科大学第二内科
-
- 三宅 速
- 香川県立中央病院内科
-
- 大林 誠一
- キナシ大林病院内科
-
- 中空 博
- 中空病院
-
- 広畑 衛
- 三豊総合病院内科
-
- 三木 茂裕
- 国療西香川病院内科
-
- 山根 行雄
- 十全総合病院内科
-
- 高杉 健太
- 住友別子病院内科
-
- 原田 篤実
- 松山赤十字病院内科
-
- 多嘉 良稔
- 松山西病院泌尿器科
-
- 白形 昌人
- 南松山病院外科
-
- 垂水 禧直
- 南松山病院内科
-
- 村上 凡平
- 村上記念病院内科
-
- 三宅 晋
- 高知県立中央病院内科
-
- 水谷 義晴
- 高知赤十字病院内科
-
- 近森 正昭
- 近森病院泌尿器科
-
- 川島 周
- 川島病院内科
-
- 玉真 捷二
- 玉真病院外科
-
- 滝下 佳寛
- 徳島県立中央病院内科
-
- 新野 秀樹
- 健康保険鳴門病院心臓血管外科
-
- 香川 征
- 徳島大学医学部泌尿器科学教室
書誌事項
- タイトル別名
-
- Study of recombinant human erythropoietin treatment on the anemia of predialysis patients.
この論文をさがす
抄録
We conducted a multiplecenter joint study on the effects of recombinant human erythropoietin (rEPO) for predialysis patients. rEPO was intravenously administered to 42 predialysis patients (13 males and 29 females) with hematocrit (Ht) levels of less than 30%. The subjects were divided into group A (28 cases)in which rEPO was administered twice a week, and group B (14 cases) with rEPO administration once a week. The initial adminis-tration dosage was 60001U/week. The Ht levels were 22.6±3.3% for group A and 23.2±2.7% for group B before the administration of rEPO, and increased to 31.0±4.0% and 27.7±3.7% respectively twelve weeks after initiating administraion. The levels of effective improvement on anemia included 'markedly effective' in 17 cases (80.9%) and 'effective' in 2 cases (9.5%) in group A, and 'markedly effective' in 5 cases (41.7%) and 'effective' in 3 cases (25.0%) in group B. No significant change was seen in serum creatinine (Cr) levels during the study period. In the evaluation of renal function by reciprocal serum creatinine (1/Cr), a consistent tendency was not recognized; thus, suggesting that the rEPO administration had no effect on the renal function. No variation of blood pressure was seen. As far as side effects were concerned, headache and heavy headedness were recognized in four cases. There were, however, no cases in which the severity of the side effects dictated the discontinuation of the rEPO administration. In conclusion, rEPO was judged to be a safe and effective treatment for the anemia of predialysis patients.
収録刊行物
-
- 日本腎臓学会誌
-
日本腎臓学会誌 34 (6), 693-700, 1992
社団法人 日本腎臓学会